RAD 105
Alternative Names: F-18 labelled; RAD-105Latest Information Update: 10 Feb 2022
At a glance
- Originator Imperial College of Science, Technology and Medicine; Radiopharm Theranostics
- Developer Radiopharm Theranostics
- Class Diagnostic agents
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 10 Feb 2022 Radiopharm Theraonostics completes a phase I trial in Solid tumors (Diagnosis) in Australia (Radiopharm Theranostics pipeline; February 2022)
- 03 Feb 2022 Phase-II clinical trials in Solid tumours (Diagnosis) in Australia (IV) (Radiopharm Theranostics pipeline; February 2022)